Agios Pharmaceuticals (NASDAQ:AGIO) Hits New 12-Month Low – Here’s What Happened

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) hit a new 52-week low on Friday . The stock traded as low as $26.03 and last traded at $26.54, with a volume of 86040 shares. The stock had previously closed at $27.71.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on AGIO shares. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. Scotiabank upped their price objective on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a report on Monday, December 9th. HC Wainwright assumed coverage on Agios Pharmaceuticals in a report on Monday, February 24th. They issued a “buy” rating and a $58.00 target price on the stock. Royal Bank of Canada upped their price target on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 10th. Finally, StockNews.com lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $56.57.

Agios Pharmaceuticals Trading Down 7.0 %

The stock has a market capitalization of $1.48 billion, a price-to-earnings ratio of 2.27 and a beta of 0.90. The firm has a 50-day moving average of $32.55 and a 200 day moving average of $40.23.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. As a group, research analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Insider Activity

In related news, insider Tsveta Milanova sold 2,804 shares of the business’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $32.18, for a total value of $90,232.72. Following the transaction, the insider now owns 18,906 shares in the company, valued at approximately $608,395.08. The trade was a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 4.93% of the company’s stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of AGIO. Venturi Wealth Management LLC bought a new stake in shares of Agios Pharmaceuticals in the fourth quarter worth $33,000. GF Fund Management CO. LTD. acquired a new position in Agios Pharmaceuticals during the 4th quarter worth $39,000. Wingate Wealth Advisors Inc. bought a new stake in shares of Agios Pharmaceuticals in the 4th quarter worth about $53,000. Sterling Capital Management LLC raised its stake in shares of Agios Pharmaceuticals by 818.0% in the 4th quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 1,587 shares in the last quarter. Finally, KBC Group NV lifted its position in shares of Agios Pharmaceuticals by 30.5% during the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 611 shares during the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.